SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Christopher D. Byrne, Giovanni Targher, NAFLD: A multisystem disease, Journal of Hepatology, 2015, 62, 1, S47

    CrossRef

  2. 2
    F. W. D. Tai, W.-K. Syn, W. Alazawi, Practical approach to non-alcoholic fatty liver disease in patients with diabetes, Diabetic Medicine, 2015, 32, 5
  3. 3
    Zoon Tariq, Charlotte J. Green, Leanne Hodson, Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?, Liver International, 2014, 34, 7
  4. 4
    Giovanni Targher, Michel B. Chonchol, Christopher D. Byrne, CKD and Nonalcoholic Fatty Liver Disease, American Journal of Kidney Diseases, 2014, 64, 4, 638

    CrossRef

  5. 5
    Yvonne Ritze, Gyöngyi Bárdos, Astrid Hubert, Maureen Böhle, Stephan C. Bischoff, Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice, British Journal of Nutrition, 2014, 112, 01, 1

    CrossRef

  6. 6
    Jaividhya Dasarathy, Pranav Periyalwar, Sanath Allampati, Vikram Bhinder, Carol Hawkins, Patricia Brandt, Amer Khiyami, Arthur J. McCullough, Srinivasan Dasarathy, Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease, Liver International, 2014, 34, 6
  7. 7
    Robin P.F. Dullaart, Eline H. van den Berg, Melanie M. van der Klauw, Hans Blokzijl, Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people, Clinical Biochemistry, 2014, 47, 12, 1028

    CrossRef

  8. 8
    Aibek E Mirrakhimov, Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?, Cardiovascular Diabetology, 2014, 13, 1, 29

    CrossRef

  9. 9
    André J Scheen, Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 6, 839

    CrossRef

  10. 10
    André J. Scheen, Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus, Clinical Pharmacokinetics, 2014, 53, 9, 773

    CrossRef

  11. 11
    Christopher D. Byrne, Ectopic fat, insulin resistance and non-alcoholic fatty liver disease, Proceedings of the Nutrition Society, 2013, 72, 04, 412

    CrossRef

  12. 12
    Yoonsu Cho, Ji Hyung Chung, Hyun Ju Do, Hyun Ju Jeon, Taewon Jin, Min-Jeong Shin, Effects of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague–Dawley rats fed on a high fat diet, Food Chemistry, 2013, 139, 1-4, 720

    CrossRef

  13. 13
    R. Rajendran, E. Abu, A. Fadl, C. D. Byrne, Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood total body irradiation, Diabetic Medicine, 2013, 30, 8
  14. 14
    Christos V. Rizos, Moses S. Elisaf, Metformin and cancer, European Journal of Pharmacology, 2013, 705, 1-3, 96

    CrossRef

  15. You have full text access to this Open Access content15
    Elaine Hui, Aimin Xu, Hong Bo Yang, Karen S L Lam, Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines, Journal of Diabetes Investigation, 2013, 4, 5
  16. 16
    Iliana Doycheva, Niraj Patel, Michael Peterson, Rohit Loomba, Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes, Journal of Diabetes and its Complications, 2013, 27, 3, 293

    CrossRef

  17. 17
    Igor P Pogribny, Frederick A Beland, Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 6, 713

    CrossRef

  18. 18
    Yoichiro Kitajima, Hideyuki Hyogo, Yoshio Sumida, Yuichiro Eguchi, Naofumi Ono, Takuya Kuwashiro, Kenichi Tanaka, Hirokazu Takahashi, Toshihiko Mizuta, Iwata Ozaki, Takahisa Eguchi, Yuki Kimura, Kazuma Fujimoto, Keizo Anzai, Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle, Journal of Gastroenterology and Hepatology, 2013, 28, 9
  19. 19
    Dawn M. Fedor, Yuriko Adkins, John W. Newman, Bruce E. Mackey, Darshan S. Kelley, The Effect of Docosahexaenoic Acid ont10,c12-Conjugated Linoleic Acid-Induced Changes in Fatty Acid Composition of Mouse Liver, Adipose, and Muscle, Metabolic Syndrome and Related Disorders, 2013, 11, 1, 63

    CrossRef

  20. 20
    Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, The Role of Skeletal Muscle in Development of Nonalcoholic Fatty Liver Disease, Diabetes & Metabolism Journal, 2013, 37, 4, 278

    CrossRef

  21. You have free access to this content21
    G. A. Hitman, Fatty liver: cause or consequence, Diabetic Medicine, 2012, 29, 9
  22. 22
    Luis A. Videla, Paulina Pettinelli, Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity, PPAR Research, 2012, 2012, 1

    CrossRef